




EUROPEAN
HEMATOLOGY
ASSOCIATION

Sunday, March 2

Time	Title
09:00-12:50	Session 8: Treatment approaches for Adolescents and Young Adults (AYAs) <i>Chairs: A. Biondi, D. Hoelzer</i>
09:00-09:25	What are the genomic differences between children and adults with ALL? <i>T. Haferlach (München)</i>
09:25-09:40	Interactive case discussion
09:40-12:20	Experience of EWALL Study groups
09:40-10:00	France <i>N. Boissel (Paris)</i>
10:00-10:20	Great Britain <i>C. Rowntree (Cardiff)</i>
10:20-10:40	Italy <i>A. M. Testi (Rome)</i>
10:40-11:00	Coffee break
11:00-11:20	Spain <i>J. Ribera (Barcelona)</i>
11:20-11:40	Poland <i>S. Giebel (Gliwice)</i>
11:40-12:00	Sweden <i>H. Hallböök (Uppsala)</i>
12:00-12:20	Germany <i>N. Gökbuget (Frankfurt)</i>
12:20-12:50	Panel discussion: Pediatric trials for younger adults: yes or no?
12:50-13:00	Conference closure
13:00-14:00	Lunch



New molecular insights in emerging therapeutic strategies in Acute Lymphoblastic Leukemia (ALL)

Dates: 28 February – 2 March 2014

Location: Lisbon, Portugal

Chair: Dieter Hoelzer

Co-chairs: Renato Bassan, Hervé Dombret, Robin Foà, Nicola Gökbuget, Josep Ribera

Early registration deadline: December 20, 2013

Preliminary Program

Friday, February 28

Time	Title
13:00-14:00	Registration
14:00-14:10	Welcome
14:10-15:50	Session 1: Genetic Alterations/Molecular Markers <i>Chairs: R. Foà, J. van Dongen</i>
14:10-14:35	Clonal hierarchy of ALL <i>E. Clappier (Paris)</i>
14:35-15:00	BCR-ABL-like ALL <i>M. den Boer (Rotterdam)</i>
15:00-15:25	Molecular genetics of T-lineage ALL <i>C. Baldus (Berlin)</i>
15:25-15:50	Joint discussion
15:50-16:20	Coffee Break
16:20-18:15	Session 2: Minimal Residual Disease/Methods and Application <i>Chairs: D. Hoelzer, A. Orfao</i>
16:20-16:45	MRD detection by PCR <i>M. Brüggemann (Kiel)</i>
16:45-17:10	Novel EuroFlow strategies for flow cytometric MRD detection <i>J. van Dongen (Rotterdam)</i>
17:10-17:35	Prognostic impact of MRD in adult ALL <i>R. Bassan (Venice)</i>
17:35-18:00	Prognostic impact of MRD in pediatric ALL <i>A. Biondi (Milano)</i>
18:00-18:45	Interactive case discussion Panel discussion: Promises and pitfalls in MRD evaluation
18:45-19:45	Welcome Reception

Saturday, March 1

Time	Title
09:00-10:05	Session 3: Diagnostics <i>Chairs: H. Dombret, T. Haferlach</i>
09:00-09:25	Comprehensive diagnostics in ALL <i>R. Foà (Rome)</i> What is needed? desirable? for research?
09:25-09:40	Interactive case discussion
09:40-10:05	A new approach for assessment of occult disease in the CSF <i>A. Orfao (Salamanca)</i>

10:05-10:55	Session 4: Targeted Therapies in Ph/Bcr-Abl Pos. ALL <i>Chairs: Cont.</i>
10:05-10:30	Next generation sequencing for BCR-ABL1 mutation detection in Ph+ leukemias <i>S. Soverini (Bologna)</i>
10:30-10:55	Targeting resistance to TKIs <i>O. Ottmann (Frankfurt)</i>
10:55-11:25	Coffee break
11:25-13:05	Session 5: Resistance and novel compounds and Targeted Therapy with Monoclonal Antibodies and Leukemia-Specific Cell Therapy <i>Chairs: N. Gökbuget, S. Giebel</i>
11:25-11:50	Novel compounds <i>S. O'Brien (Houston)</i>
11:50-12:15	Anti-CD19 <i>M. Topp (Würzburg)</i>
12:15-12:40	Anti-CD22 <i>S. O'Brien (Houston)</i>
12:40-13:05	CART cells in ALL <i>R. Brentjens (New York)</i>
13:30-14:45	Lunch
14:45-16:00	Session 6: Current treatment strategies and results <i>Chairs: R. Bassan, S. O'brien</i>
16:00-16:20	Risk stratification in T-lineage ALL <i>H. Dombret (Paris)</i>
14:45-16:10	Risk stratification in B-lineage ALL <i>J. Ribera (Barcelona)</i>
15:10-15:35	Elderly ALL – challenging concepts; from palliative care to cure <i>N. Gökbuget (Frankfurt)</i>
15:35-16:00	Coffee Break
16:00-16:30	Session 7: Stem cell transplantation <i>Chairs: J. Ribera, O. Ottmann</i>
16:30-16:55	SCT in CR1 – indications <i>J. Cornelissen (Rotterdam)</i>
16:55-17:20	Autologous SCT - Recent update of EBMT results <i>S. Giebel (Gliwice)</i>
17:20-17:45	Haplo-identical SCT <i>F. Ciceri (Milan)</i>
17:45-18:45	Round table discussion: Experience with regulation rules and drug reimbursement for ALL